CEO Address: I am

CEO Address:

I am excited to report that OncoSec is continuing to execute on the corporate milestones which were set in the beginning of 2012 .

We have just announced positive preliminary efficacy and safety results for patients who are still undergoing treatment in our Merkel cell carcinoma (MCC) program. One patient with progressive MCC who had no success with any past treatments, showed a 70% regression in tumors (including distant tumors). You can find out more about MCC and why this data is significant to our company on our blog .

In addition, we will host the first symposium for ImmunoPulse at the prestigious European Association of Dermato-Oncology (EADO) Congress on November 14-17. At this meeting, early data will also be presented for the first time on our ongoing Phase II metastatic melanoma program.

Looking ahead, we see some potentially exciting catalysts that will continue to build value for our shareholders and advance our programs to commercialization. Again, thank you for being a vital part of providing a new hope for people dealing with advanced stage skin cancer and your continued support of our progress at OncoSec.

Punit Dhillon